Financials
- Financial year
- 2025
- Total assets
- €501,766
- Profit
- €25,057
- Solvency
- 9.0%
3D Fibroscreen
ActiveSummary
3D Fibroscreen has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €45,057 and a net result of €25,057. Its solvency ranks better than 19% of 610 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Activity
Research and development on biotechnology
NACE 72101
2 sites
Size
€501,766total assets 2025
- Equity
- €45,057
- Profit
- €25,057
Turnover not published (micro format)
Structure
Accounts filed 33 days late
Why 89raises risk1 change of registered office in 24 monthsLatest accounts 33 days late; 1 of the last 3 latelowers riskLiquidity: current ratio 69.74, cash €464,675Sector: Scientific research and development (NACE 72)Show the evidence
Checked score
Score 2025
89
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 56% of its sector peers (NACE 72, micro)
Financial strength
Strong
Solvency
34
equity 9.0% of total assets
Liquidity
100
short-term debt 1.3% · cash 92.6%
Profitability
75
return on assets 5.0%
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
05-2026: 1.3%
06-2026: 1.3%● unchanged vs 05-2026
07-2026: 1.3%● unchanged vs 06-2026
08-2026: 1.4%▲ +0.1 percentage points vs 07-2026
09-2026: 1.4%● unchanged vs 08-2026highest value
10-2026: 0.2%▼ -1.2 percentage points vs 09-2026lowest value
Credit of up to €4,000 on 30-day terms is acceptable
Liquidity ample (current ratio 69.74, above the usual 1.5; short-term debt: 1.3% and cash: 92.6% of total assets), but 91% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro): better than 23% on solvency, 96% on liquidity and 50% on profitability.
The bankruptcy probability was computed on 15-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Seven signals.
lowers riskraises riskneutral
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 19% of 610 sector peers (2025).
NBB · sector comparisonPosition among 610 sector peers
Solvency
better than 19%
← weakest
strongest →
raises risk · Young company
Founded in 2025, a year ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-09-2026, 33 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 1 filingDeviation from the deadline
2025
33 days late
← before the deadline
after the deadline →
Searched, nothing found (1)
- Annual accounts filedfinancial year 2025 · micro…
- Registered officeRegistered-office move · Power of…
- IncorporationAppointments: BASE CAMP, JOUY Charlène…
Key points
By topic
Timeline
- Events
- 3
- Since
- 2025
Company details
- Sites
- 2
- Legal form
- Private limited company
- Activity
- Research and development on biotechnologyNACE 72101
- Founded
- 28-04-2025
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 19
- Annual meeting
- First Wednesday of June at 10:00
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Roughly what is this company worth?Value indication
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.